Nurix Therapeutics (NASDAQ:NRIX) reported insider activity by Chief Financial Officer Hans van Houte on January 30, 2026. On that date van Houte sold a combined 3,661 shares of the companys common stock in two separate transactions, with execution prices spanning $16.5826 to $17.3717. The disposals generated net proceeds of approximately $60,766.
Also on January 30, van Houte took delivery of shares tied to previously granted restricted stock units. A total of 11,496 shares of Nurix common stock were acquired at an exercise price of $0 per share.
These insider moves took place against the backdrop of multiple analyst reactions to Nurixs fourth-quarter 2025 financial disclosure. The company reported a net loss of $0.82 per share for the period, a result that was marginally better than H.C. Wainwrights estimate of a $0.84 per share loss.
In response to the quarter, H.C. Wainwright raised its price target for Nurix to $32 and maintained a Buy rating. Piper Sandler elevated its target to $35, calling attention to accelerated development plans for Nurixs bexobrutideg treatment in chronic lymphocytic leukemia and small lymphocytic lymphoma. Stifel also increased its price target to $35, highlighting 2026 as a key year for the bexobrutideg program.
RBC Capital lifted its target to $30 and characterized the companys recent operational updates as consistent with prior communications. BTIG reiterated a Buy rating and set a $30 price objective, pointing to Nurixs strong cash position and progress across important programs.
Taken together, the insider transaction and the cluster of analyst target increases show concurrent activity in Nurixs corporate ownership and external assessments of the companys prospects. The facts presented here are limited to the reported transactions and the published analyst actions; no additional corporate commentary or interpretation was provided alongside the disclosures.
Contextual note: The sale, the RSU exercise, and the successive analyst updates occurred on or after Nurixs fourth-quarter 2025 reporting and reflect the data and evaluations disclosed by the named analysts and the companys executive filings.